4//SEC Filing
Cittadine Andrew 4
Accession 0001437749-25-000097
CIK 0001645469other
Filed
Jan 1, 7:00 PM ET
Accepted
Jan 2, 6:15 PM ET
Size
9.1 KB
Accession
0001437749-25-000097
Insider Transaction Report
Form 4
Cittadine Andrew
Chief Operating Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2024-12-31−1,790→ 11,074 total→ Common Stock (1,790 underlying) - Exercise/Conversion
Common Stock
2024-12-31+1,790→ 41,659 total - Tax Payment
Common Stock
2024-12-31$22.00/sh−721$15,862→ 40,938 total
Footnotes (4)
- [F1]Represents shares acquired on vesting and settlement of restricted stock units.
- [F2]Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
- [F3]On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
- [F4]On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
Documents
Issuer
Monopar Therapeutics
CIK 0001645469
Entity typeother
Related Parties
1- filerCIK 0001863624
Filing Metadata
- Form type
- 4
- Filed
- Jan 1, 7:00 PM ET
- Accepted
- Jan 2, 6:15 PM ET
- Size
- 9.1 KB